Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 881.59% | 104.20% | -651.49% | 79.79% | -170.56% |
| Total Depreciation and Amortization | -3.85% | 133.77% | -396.15% | 4.00% | -3.85% |
| Total Amortization of Deferred Charges | -- | -- | 125.00% | -7.69% | 0.00% |
| Total Other Non-Cash Items | 58.70% | -88.25% | 1,357.59% | -79.26% | 200.46% |
| Change in Net Operating Assets | -382.72% | 113.35% | -688.87% | 148.13% | 21.13% |
| Cash from Operations | -97.90% | 139.90% | -499.33% | 140.50% | 14.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 48.22% | -96.87% | 2,248.75% | -- | -- |
| Repurchase of Common Stock | -202.57% | -1,096.15% | 48.00% | 82.39% | -2,266.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.79% | -95.14% | 1,089.42% | 715.85% | -179.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.45% | -77.15% | 357.77% | 181.66% | -0.28% |